S TIER 🔴

Retatrutide (GLP-3 metabolic peptide)

Triple pathway GLP1 GIP Glucagon agonist.

This is the one everyone calls GLP-3 because it hits more switches at the same time than semaglutide or tirzepatide.

GLP1 balances blood sugar

(GLP1 controls appetite signals and slows digestion)

GIP improves carb handling

(GIP helps your body pull glucose into muscle and not fat)

Glucagon increases metabolic heat

(Glucagon raises resting calorie burn and fat oxidation)

Retatrutide also supports

• Higher NEAT output

• Stronger satiety signaling

• Faster body recomp in overweight users

• More consistent fat loss curves at lower doses Great for people who want aggressive appetite control, higher output, and the fastest fat loss curve of the GLP family. Check out the study for yourself --> https://pubmed.ncbi.nlm.nih.gov/37366315/ 📘 Full breakdown guide coming soon.

Tirzepatide (dual pathway fat loss peptide)
GLP1 plus GIP.
Smooth energy, strong appetite suppression, and usually faster fat loss than semaglutide.
Extra benefits you don’t see listed often

• Higher carb tolerance during diets

• Lower insulin spikes from cheat meals

• Better appetite control in the evenings

• Less nausea when dosed correctly Good for people who want rapid fat loss without the intensity of retatrutide. Check out the study for yourself --> https://pubmed.ncbi.nlm.nih.gov/40353578/ 📘 Full breakdown coming soon.

BPC-157 (healing peptide)
Regulates tissue repair signaling and inflammation control.
Angiogenesis support
(creates new blood vessels that deliver nutrients to damaged areas)
Collagen modulation
(signals repair for tendons, ligaments, joints, and GI tissue)
What makes BPC stand out

• Speeds gut lining repair

• Helps nagging tendon issues

• Supports post surgery inflammation

• Helps mobility when stacked with TB500 Great for older individuals healing slower, athletes recovering from strain, and people with gut inflammation. Check out the study for yourself --> https://pubmed.ncbi.nlm.nih.gov/14554208/ 📘 Full breakdown coming soon.